查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1574135

基因组学人工智慧 (AI) 市场：2024-2029 年预测

Artificial Intelligence (AI) in Genomics Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

基因组学领域的人工智慧 (AI) 市场预计将从 2024 年的 1,904,018,000 美元增加到 2029 年的 7,785,766,000 美元，预测期内复合年增长率为 32.53%。

随着对精准医疗和针对特定健康疾病的标靶治疗的需求不断增加，基因组学领域的人工智慧市场正在快速成长。由于基因组学研究倡议的激增以及对更好的资料管理和整合解决方案的需求不断增长，预计该市场将扩大。该市场应用于药物发现、疾病诊断和治疗规划的各个领域，有助于发现新的药物标靶并提高治疗效果。

此外，可以透过分析用于疾病诊断的大型资料组资料集集来识别早发疾病讯号，并根据患者的病情量身定制治疗计划。人工智慧可以根据基因组序列转变临床指南，进一步优化治疗结果。

基因组学市场人工智慧的驱动因素：

  • 人工智慧技术在各个领域的日益普及预计将扩大基因组学领域人工智慧的全球市场。

精准医学正在扩大基因组学领域的人工智慧市场。精准医学考虑到一个人独特的基因组成、外部条件和生活方式的决定，以製定快速采取行动的个人化治疗计划。人工智慧技术的进步可以处理大规模基因组资料来识别模式，根据能力和相似性将它们关联起来，并帮助启动个人化治疗。

此外，人工智慧正在被纳入某些领域（主要是癌症）的医疗保健和治疗领域的精准医疗应用。人工智慧可用于分析基因组资料、癌症突变的基因组成，并识别有利于患者康復的最佳治疗方法。它还可以识别出患有某些癌症的高风险族群，从而实现更早检测和更有针对性的治疗。随着癌症患者数量的增加，基因组学领域的人工智慧市场可能会看到机会。

根据国际癌症控制联盟（UICC）预测，到2050年，新增癌症患者将超过3500万人。预计这一数字将比 2022 年报告的约 2,000 万人增加 77%。低 HDI 国家的绝对增幅最大，为 142%，其次是中等 HDI 国家，为 99%。同时，到 2050 年，这些国家的癌症死亡人数预计将增加近一倍。

基因组学市场中人工智慧的地理格局：

  • 北美地区预计将占据人工智慧工程市场的重要份额。

北美是基因组学人工智慧的重要市场，因为该地区拥有大量的基因组学公司、基因组学研究的大量资金筹措以及医疗保健系统的开发。此外，基于人工智慧的基因组学产品和应用的进步以及对个人化治疗的需求不断增长正在推动未来几年的市场扩张。

此外，在美国和加拿大等北美国家，随着政府和私人组织增加对基因组研究的投资，人工智慧在医疗保健领域的采用正在增加。此外，庞大的患者基础也可能推动该地区的市场扩张。

为什么要购买这份报告？

  • 洞察分析：深入洞察关键和新兴地区的市场，重点关注客户群、政府政策和社会经济因素、消费者偏好、产业领域和其他子区隔。
  • 竞争格局：了解世界主要企业采取的策略策略，并了解透过正确的策略渗透市场的潜力。
  • 市场驱动因素和未来趋势：探索动态因素和关键市场趋势以及它们将如何塑造未来市场开拓。
  • 可行的建议：利用洞察力做出策略决策，在动态环境中释放新的业务流和收益。
  • 面向广大受众：对于新兴企业、研究机构、顾问、中小型企业和大型企业有用且具有成本效益。

公司使用我们的报告的目的是什么？

产业和市场考量、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范与影响、新产品开拓、竞争影响

调查范围

  • 过去的资料/预测，2022-2029
  • 成长机会、挑战、供应链前景、法规结构、顾客行为、趋势分析
  • 竞争对手的市场状况、策略与市场占有率分析
  • 包括国家在内的细分市场和地区的收益成长和预测评估
  • 公司简介（策略、产品、财务资讯、主要发展等）

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章 基因组学中的人工智慧市场：透过提供

  • 介绍
  • 软体工具
  • 服务

第六章 基因组学中的人工智慧市场：按应用分类

  • 介绍
  • 精准医疗
  • 诊断/预后
  • 药物发现/药物开发
  • 农业和畜牧业
  • 其他的

第七章 基因组学中的人工智慧市场：按最终用户划分

  • 介绍
  • 製药和生物技术公司
  • 学术/研究机构
  • 医院/诊断中心
  • 其他的

第八章 基因组学人工智慧市场：按地区

  • 介绍
  • 北美洲
    • 透过提供
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 南美洲
    • 透过提供
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 欧洲
    • 透过提供
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 中东/非洲
    • 透过提供
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 亚太地区
    • 透过提供
    • 按用途
    • 按最终用户
    • 按国家/地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • IBM
  • Sophia Genetics SA
  • QIAGEN NV
  • Fabric Genomics, Inc.
  • Congenica Ltd.
  • Illumina, Inc.
  • Freenome Holdings, Inc.
  • Data4cure, Inc.
  • Tempus Labs, Inc.
  • NVIDIA Corporation
简介目录
Product Code: KSI061614431

Artificial Intelligence (AI) in the Genomics Market is projected to witness a CAGR of 32.53% during the forecast period to reach a total market size of US$7,785.766 million by 2029, up from US$1,904.018 million in 2024.

The AI in the genomics market is growing rapidly with the rising demand for precision drugs and targeted therapies for specific health disorders. The market is anticipated to expand due to the burgeoning genomics research initiatives and the increasing demand for better data management and integration solutions. It is employed in all areas of drug discovery, disease diagnosis, and treatment planning to find new drug targets and improve therapeutic efficacy.

Moreover, it can analyze large genomic data datasets for disease diagnostics and identify early-onset disease signals by customizing the treatment planning per the patient's condition. AI could additionally optimize treatment results by transforming the clinical guidelines according to the genome sequence, with AI detecting a new way into the genomics market in the future.

AI IN GENOMICS MARKET DRIVERS:

  • Growing adoption of AI technology across different sectors is expected to increase the global market for AI in genomics.

Precision medicine is expanding the market for AI in genomics. Precision medicine considers an individual's unique genetic makeup, external conditions, and lifestyle decisions to create personalized treatment plans that take action rapidly. AI technological advancements can process large cohorts of genomic data to identify patterns and correlate them depending on capability or similarity, assisting in initiating personalized treatments.

Furthermore, AI has been incorporated into precision medicine applications in healthcare and treatment concerning some areas, mainly cancer. AI can be used to analyze genomic data, i.e., the genetic makeup of a mutation in cancer, and recognize the best therapies beneficial for the patient's recovery. It can also be harnessed to identify people who have an increased risk of developing certain cancers, facilitating earlier detection and more targeted treatment capabilities. The market for AI in genomics is potentially finding opportunities with growing cancer cases.

According to the Union for International Cancer Control (UICC), by 2050, an estimated over 35 million new cancer cases are projected to occur. This figure is a predicted increase of 77% from approximately 20 million reported in 2022. The most substantial absolute increases are for low HDI countries, with an increment of 142%, followed by medium-HDI countries, with a rise of 99%. At the same time, cancer deaths are expected to nearly double in these countries by 2050.

AI In Genomics Market Geographical Outlook:

  • The North American region is expected to hold a substantial artificial intelligence engineering market share.

North America is a significant market for AI in genomics due to numerous genomics firms, significant financing in genomics research, and a developed healthcare system. Additionally, the advancement of AI-based genomics products and applications, as well as the rising demand for personalized treatment, are propelling market expansion in the coming years.

Moreover, North American countries like the United States and Canada are increasing the employment of AI in healthcare, and government and private organizations are increasing investments in genomics studies. Further, the presence of a sizable patient base will also promote the advancement of the market in the region.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2029
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Market Segmentation:

The AI in Genomics Market is segmented and analyzed as below:

By Offering

  • Software tools
  • Services

By Application

  • Precision medicine
  • Diagnosis and prognosis
  • Drug discovery and development
  • Agriculture and animal breeding
  • Others

By End-User

  • Pharmaceutical and biotechnology companies
  • Academic and research institutes
  • Hospitals and diagnostic centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Vietnam
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. AI IN GENOMICS MARKET BY OFFERING

  • 5.1. Introduction
  • 5.2. Software tools
  • 5.3. Services

6. AI IN GENOMICS MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Precision medicine
  • 6.3. Diagnosis and prognosis
  • 6.4. Drug discovery and development
  • 6.5. Agriculture and animal breeding
  • 6.6. Others

7. AI IN GENOMICS MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Pharmaceutical and biotechnology companies
  • 7.3. Academic and research institutes
  • 7.4. Hospitals and diagnostic centers
  • 7.5. Others

8. AI IN GENOMICS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Offering
    • 8.2.2. By Application
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Offering
    • 8.3.2. By Application
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Offering
    • 8.4.2. By Application
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Offering
    • 8.5.2. By Application
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. Israel
      • 8.5.4.3. UAE
      • 8.5.4.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Offering
    • 8.6.2. By Application
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. India
      • 8.6.4.4. South Korea
      • 8.6.4.5. Australia
      • 8.6.4.6. Vietnam
      • 8.6.4.7. Indonesia
      • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. IBM
  • 10.2. Sophia Genetics SA
  • 10.3. QIAGEN N.V.
  • 10.4. Fabric Genomics, Inc.
  • 10.5. Congenica Ltd.
  • 10.6. Illumina, Inc.
  • 10.7. Freenome Holdings, Inc.
  • 10.8. Data4cure, Inc.
  • 10.9. Tempus Labs, Inc.
  • 10.10. NVIDIA Corporation